S&P Futures
4,305.00 -2.75 (-0.06%) Dow Futures
34,099.00 -19.00 (-0.06%) Nasdaq Futures
13,645.00 -13.25 (-0.10%) Russell 2000 Futures
2,022.50 -0.80 (-0.04%) Crude Oil
86.99 +0.46 (+0.53%) Gold
1,790.50 +0.80 (+0.04%)
Generation Bio Co. (GBIO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 7.92 |
| Open | 7.82 |
| Bid | 7.15 x 1200 |
| Ask | 7.28 x 1000 |
| Day's Range | 7.14 - 7.97 |
| 52 Week Range | 3.96 - 28.67 |
| Volume | |
| Avg. Volume | 373,088 |
| Market Cap | 410.889M |
| Beta (5Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.10 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
- Zacks
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results
Cash balance of $312.2M expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progre
- GlobeNewswire
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be avai
